B G P Koot1, O H van der Baan-Slootweg2, S Vinke1, A E Bohte3, C L J Tamminga-Smeulders2, P L M Jansen4, J Stoker3, M A Benninga1. 1. Department of Paediatric Gastroenterology, Emma Children's Hospital/Academic Medical Centre, Amsterdam, The Netherlands. 2. Childhood Obesity Centre Heideheuvel, Hilversum, The Netherlands. 3. Department of Radiology, Academic Medical Centre, Amsterdam The Netherlands. 4. Department of Hepatology, Academic Medical Centre, Amsterdam, The Netherlands.
Abstract
BACKGROUND/AIMS: Lifestyle intervention is the only established therapy for non-alcoholic fatty liver disease (NAFLD). The optimal treatment schedule and predictors of response of this treatment have not been established in children. We aimed to evaluate the 2-year efficacy of an inpatient versus ambulatory intensive lifestyle intervention for treating NAFLD in children with severe obesity. METHODS: A cohort study of 51 severely obese non-diabetic children (mean age 14.7 (±2.4) years; BMI-z-score 3.5 (±0.5)) with liver steatosis were non-randomly allocated to inpatient treatment (2 or 6 months), ambulatory treatment or usual care. Proton Magnetic Resonance Spectroscopy determined liver steatosis and serum alanine aminotransferase (ALT) at 6 months were the primary outcome measures. Baseline variables were evaluated as predictors of treatment response. RESULTS: Liver steatosis had disappeared in 43, 29 and 22% and serum ALT normalized in 41, 33 and 6% at the end of 6 months in the inpatient, ambulatory or usual care treatment groups, respectively. Only the proportions of ALT normalization in inpatient and ambulatory treatment compared with usual care were significantly higher. Treatment effects of inpatient and ambulatory treatment were sustained at 1.5 years follow-up. No baseline characteristic, including PNPLA3 polymorphism or leptin, was consistently predictive for treatment response. CONCLUSIONS: A 6-month intensive inpatient and ambulatory lifestyle treatment in children with severe obesity reverses NAFLD in a minority of patients. This study suggests that inpatient compared with ambulatory intensive treatment does not importantly increase treatment success. Further efforts to optimize and individualize lifestyle interventions and additional treatments options are needed particular for children with severe obesity resistant to conventional lifestyle interventions.
BACKGROUND/AIMS: Lifestyle intervention is the only established therapy for non-alcoholic fatty liver disease (NAFLD). The optimal treatment schedule and predictors of response of this treatment have not been established in children. We aimed to evaluate the 2-year efficacy of an inpatient versus ambulatory intensive lifestyle intervention for treating NAFLD in children with severe obesity. METHODS: A cohort study of 51 severely obese non-diabeticchildren (mean age 14.7 (±2.4) years; BMI-z-score 3.5 (±0.5)) with liver steatosis were non-randomly allocated to inpatient treatment (2 or 6 months), ambulatory treatment or usual care. Proton Magnetic Resonance Spectroscopy determined liver steatosis and serum alanine aminotransferase (ALT) at 6 months were the primary outcome measures. Baseline variables were evaluated as predictors of treatment response. RESULTS:Liver steatosis had disappeared in 43, 29 and 22% and serum ALT normalized in 41, 33 and 6% at the end of 6 months in the inpatient, ambulatory or usual care treatment groups, respectively. Only the proportions of ALT normalization in inpatient and ambulatory treatment compared with usual care were significantly higher. Treatment effects of inpatient and ambulatory treatment were sustained at 1.5 years follow-up. No baseline characteristic, including PNPLA3 polymorphism or leptin, was consistently predictive for treatment response. CONCLUSIONS: A 6-month intensive inpatient and ambulatory lifestyle treatment in children with severe obesity reverses NAFLD in a minority of patients. This study suggests that inpatient compared with ambulatory intensive treatment does not importantly increase treatment success. Further efforts to optimize and individualize lifestyle interventions and additional treatments options are needed particular for children with severe obesity resistant to conventional lifestyle interventions.
Authors: Olga van der Baan-Slootweg; Marc A Benninga; Anita Beelen; Job van der Palen; Christine Tamminga-Smeulders; Jan G P Tijssen; Wim M C van Aalderen Journal: JAMA Pediatr Date: 2014-09 Impact factor: 16.193
Authors: Henning Grønbæk; Aksel Lange; Niels H Birkebæk; Peter Holland-Fischer; Jan Solvig; Arne Hørlyck; Kurt Kristensen; Søren Rittig; Hendrik Vilstrup Journal: J Pediatr Gastroenterol Nutr Date: 2012-02 Impact factor: 2.839
Authors: Jeffrey B Schwimmer; Reena Deutsch; Jeffrey B Rauch; Cynthia Behling; Robert Newbury; Joel E Lavine Journal: J Pediatr Date: 2003-10 Impact factor: 4.406
Authors: Jeffrey B Schwimmer; Winston Dunn; Gregory J Norman; Perrie E Pardee; Michael S Middleton; Nanda Kerkar; Claude B Sirlin Journal: Gastroenterology Date: 2010-01-11 Impact factor: 22.682
Authors: José Ignacio Martínez-Montoro; Isabel Cornejo-Pareja; Ana María Gómez-Pérez; Francisco J Tinahones Journal: Nutrients Date: 2021-11-15 Impact factor: 5.717